Dose escalation of oral vinorelbine in combination with estramustine in hormone‐refractory adenocarcinoma of the prostate
Authors:
- Rodney L. DunnRDRodney L. Dunn
- Kathleen A. CooneyKCKathleen A. Cooney
- Judith FardigJFJudith Fardig
- Karin OlsonKOKarin Olson
- Kenneth J. PientaKPKenneth J. Pienta
- David C. SmithDSDavid C. Smith
Open Access
Abstract
BACKGROUND: The primary objective of the current study was to identify the tolerable dose level of oral vinorelbine when given in combination with estramustine to men with hormone‐refractory prostate cancer (HRPC). The secondary objectives were to describe the toxicities of the combined regimen in patients with HRPC and to estimate the efficacy of oral vinorelbine in combination with estramustine based on the prostate‐specific antigen (PSA) response.METHODS: Thirty‐three patients with HRPC were treated on a 28‐day cycle with estramustine at a dose of 140 mg orally 3 times a day on Days 1‐3 and 8‐10. Vinorelbine was given orally on Days 2 and 9. The initial dose of vinorelbine was 50 mg/m2 and was escalated to 70 mg/m2 using the time‐to‐event continual reassessment method.RESULTS: Three of 17 patients experienced dose‐limiting toxicity at the 70 mg/m2 dose level of oral vinorelbine. One patient experienced dose‐limiting toxicity at a dose of 60 mg/m2 and no dose‐limitig toxicities were reported at the 50 mg/m2 dose. The overall response rate by ≥50% reduction in PSA was 17.2%, (95% confidence interval, 5.9‐35.8%).CONCLUSIONS: Oral vinorelbine at doses of 70 mg/m2 may be safely combined with estramustine. The combination appears to have modest activity in men with advanced prostate cancer. The trial design employed the time‐to‐event continual reassessment method, which potentially allows for rapid accrual, a more complete assessment of toxicities, and a larger fraction of patients to be treated at an effective dose. More active regimens are needed to further evaluate the utility of this clinical trial design in patients with prostate cancer. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 18 references indexed in Scilit:
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancerUrologic Oncology: Seminars and Original Investigations, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinomaCancer, 2003
- A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancerAnnals of Oncology, 2002
- A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)The Prostate, 2001
- Sequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesBiometrics, 2000
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubulesInternational Journal of Cancer, 1990